Odyssey Health, Inc. (ODYY) Q2 2026 Financial Results: Critical Updates for Investors

Executive Summary

Odyssey Health, Inc. (OTC: ODYY) has released its unaudited financial statements for the quarter ended January 31, 2026. The report contains several important developments that current and prospective shareholders must consider, as they may have significant implications for the company’s future operations and share value.

Key Financial Highlights

• Net Loss Widens Substantially: Odyssey Health reported a net loss of \$3,601,623 for the quarter ended January 31, 2026, compared to a net loss of \$220,126 for the same period in the prior year. The company’s accumulated deficit now stands at (\$62,830,907) as of January 31, 2026, up from (\$62,242,178) at July 31, 2025.
• Stockholders’ Deficit Increases: Total stockholders’ deficit ballooned to (\$10,595,819) as of January 31, 2026, from (\$6,462,820) at July 31, 2025.
• Cash Position Remains Critically Low: Cash and cash equivalents at the end of the period were only \$49,723, emphasizing the company’s ongoing liquidity challenges.
• Financing Costs Surge: Odyssey incurred \$3,080,023 in financing costs during the six months ended January 31, 2026—an enormous increase compared to the prior year, signaling expensive fundraising or restructuring efforts.
• Dilution via Equity Issuance: The company issued common stock for the conversion of outstanding principal totaling \$144,000 and saw shares outstanding rise from 96,709,763 to 99,853,763 during the period—an explicit dilution risk for existing shareholders.
• Derivatives and Warrants: Odyssey issued warrants in debt financing, resulting in additional paid-in capital of \$56,589 in the first quarter and continued changes in the fair value of derivative liabilities. As of January 31, 2026, the fair value of derivative liabilities recorded was \$3,936,166.

Operational and Strategic Updates

• Business Model and Outlook:
  Odyssey continues to pursue a strategy focused on creating or acquiring assets, IP, and technologies with a strong focus on unmet medical needs. The company’s aim is to advance products through clinical development and regulatory approval, then commercialize or out-license for revenue.
• Liquidity Risk and Going Concern:
  The company explicitly states that there is substantial doubt about its ability to continue as a going concern due to recurring operating losses, negative cash flows, and a significant accumulated deficit. Odyssey Health needs to secure additional capital or external financing to maintain operations. If unsuccessful, the company may be forced to scale back or cease operations entirely.
• Potential Dilution and Leverage:
  Management warns that additional equity issuances could severely dilute current shareholders, and new debt financing would further increase liabilities and cash commitments.
• Stockholder Information:
  As of March 11, 2026, there were 99,853,763 shares of common stock outstanding. No preferred stock is outstanding. The company’s shares trade under the symbol ODYY on the OTC market.
• Loss Per Share:
  For the quarter, basic and diluted net loss per share was (\$0.03), and for the six-month period, (\$0.04).

Regulatory and Accounting Developments

• New Accounting Standards:
  Odyssey is preparing for the adoption of FASB ASU 2023-09 (Income Tax Disclosures) for the fiscal year ending July 31, 2026, and ASU 2024-03 (Disaggregation of Income Statement Expense) for the year ending July 31, 2027. These will not materially affect reported results but may change disclosure practices.
• Segment Reporting:
  Odyssey operates as a single reportable segment under ASC 280.

Critical Issues for Shareholders and Potential Price-Moving Events

• Going Concern Doubt: The explicit going concern warning is highly price-sensitive and could significantly impact market confidence and the share price.
• Potential for Further Dilution: Ongoing and future share issuances to raise capital may lead to share price pressure and dilution of existing holdings.
• Liquidity Crisis: The company’s extremely low cash balance and heavy financing costs highlight immediate financial risks.
• Increased Leverage and Derivative Exposure: A large and growing derivative liability coupled with high financing costs could affect future results and the company’s ability to refinance or restructure.
• No Preferred Stock Outstanding: The capital structure is currently all common equity, but the risk of new preferred or other dilutive instruments remains.

Conclusion

Odyssey Health, Inc. is in a critical financial position. The combination of a widening net loss, negative stockholders’ equity, minimal cash, and the urgent need to raise capital creates substantial uncertainty about the company’s future. Shareholders should be aware of the acute risks of further dilution, possible default, or even bankruptcy if additional funding cannot be secured. Conversely, any successful capital raise, business development, or licensing deal could cause volatility and move the share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with their financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties. The company’s actual results may differ materially from those discussed.

View Odyssey Health, Inc. Historical chart here